Myles Minter
Stock Analyst at William Blair
(1.31)
# 3,534
Out of 4,959 analysts
18
Total ratings
52.94%
Success rate
-9.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Initiates: Outperform | n/a | $23.65 | - | 1 | Jul 2, 2025 | |
| IMUX Immunic | Initiates: Outperform | n/a | $0.94 | - | 1 | Mar 25, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | n/a | $1.59 | - | 1 | Nov 5, 2024 | |
| ARGX argenx SE | Upgrades: Outperform | n/a | $663.73 | - | 2 | Nov 1, 2024 | |
| KRRO Korro Bio | Initiates: Outperform | n/a | $20.55 | - | 1 | Aug 14, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | n/a | $1.64 | - | 1 | Oct 10, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Outperform | $71 | $17.48 | +306.18% | 1 | Jul 24, 2023 | |
| MRNA Moderna | Initiates: Market Perform | n/a | $26.22 | - | 1 | Jul 24, 2023 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $397.46 | - | 1 | May 30, 2023 | |
| LRMR Larimar Therapeutics | Upgrades: Outperform | n/a | $3.69 | - | 3 | Sep 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $467.55 | - | 1 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $43.24 | - | 2 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.27 | - | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $116 | $135.28 | -14.25% | 1 | Feb 24, 2020 |
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $23.65
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.94
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.59
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $663.73
Upside: -
Korro Bio
Aug 14, 2024
Initiates: Outperform
Price Target: n/a
Current: $20.55
Upside: -
Neumora Therapeutics
Oct 10, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.64
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $17.48
Upside: +306.18%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $26.22
Upside: -
Vertex Pharmaceuticals
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $397.46
Upside: -
Larimar Therapeutics
Sep 19, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.69
Upside: -
Jun 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $467.55
Upside: -
Dec 14, 2021
Upgrades: Outperform
Price Target: n/a
Current: $43.24
Upside: -
Sep 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.27
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: $116
Current: $135.28
Upside: -14.25%